SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/27/22 Progyny, Inc. 8-K:5 5/25/22 10:168K Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 39K 5: R1 Document and Entity Information HTML 46K 8: XML IDEA XML File -- Filing Summary XML 11K 6: XML XBRL Instance -- pgny-20220525x8k_htm XML 15K 7: EXCEL IDEA Workbook of Financial Reports XLSX 6K 3: EX-101.LAB XBRL Labels -- pgny-20220525_lab XML 44K 4: EX-101.PRE XBRL Presentations -- pgny-20220525_pre XML 30K 2: EX-101.SCH XBRL Schema -- pgny-20220525 XSD 12K 9: JSON XBRL Instance as JSON Data -- MetaLinks 11± 16K 10: ZIP XBRL Zipped Folder -- 0001558370-22-009468-xbrl Zip 10K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i May 25, 2022
i Progyny, Inc.
(Exact name of Registrant as Specified in Charter)
| | |
i Delaware | i 27-2220139 | |
(State
or Other Jurisdiction | (Commission | (IRS Employer |
( i 212) i 888-3124
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
i Common Stock, $0.0001 par value per share | | i PGNY | | i The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders
Progyny, Inc. (“Progyny” or “our”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) on May 25, 2022. Stockholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in Progyny’s Proxy Statement filed with the Securities and Exchange Commission on April 14, 2022. The results were as follows:
1. | Proposal 1 - Election of Directors |
Each of the Class III director nominees to our board of directors (the “Board of Directors”) was elected to serve until Progyny’s 2025 Annual Meeting of Stockholders and until his or her successor has been duly elected, or if sooner, until he or she resigns, dies, or is removed from the Board of Directors.
| | | |
Director Nominee | Votes For | Votes Withheld | Broker Non-Votes |
Dr. Fred E. Cohen | 54,837,777 | 23,959,334 | 4,930,652 |
Dr. Norman Payson | 47,869,440 | 30,927,631 | 4,930,652 |
Dr. Beth Seidenberg | 54,866,543 | 23,930,568 | 4,930,652 |
2. | Proposal 2 – Ratification of Ernst & Young LLP as our Independent Registered Public Accounting Firm |
Stockholders ratified the appointment of Ernst & Young LLP as Progyny’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
| | |
Votes For | Votes Against | Abstentions |
83,431,487 | 252,513 | 43,673 |
3. | Proposal 3 – Approval, on a Non-Binding Advisory Basis, of the Compensation of our Named Executive Officers |
Stockholders approved, on a non-binding advisory basis, the compensation paid to Progyny’s named executive officers for the fiscal year ending December 31, 2022.
| | | | | ||
Votes For | Votes Against | Abstentions | ||||
77,734,833 | 1,011,237 | 51,041 | ||||
| | | | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| Progyny, Inc. | |
| | |
Dated: May 27, 2022 | | |
| By: | /s/ Peter Anevski |
| | |
| | Chief Executive Officer |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
12/31/22 | ||||
Filed on: | 5/27/22 | |||
For Period end: | 5/25/22 | 4, DEF 14A | ||
4/14/22 | DEF 14A, DEFA14A | |||
List all Filings |